Takeda reports positive cancer-study results. Takeda stock trades at EUR 18.00 in weekend trading
Published on 10/25/2026 at 17:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical readout and next session
- Takeda reported median overall survival of 10.2 months versus 6.9 months on October 23, 2026.
- Takeda stock was at EUR 18.00 in weekend trading at Lang & Schwarz at 5:03 p.m. CET on October 25, 2026.
- The next Xetra session is scheduled for October 26, 2026.
Takeda reported positive results from the Phase 3 G-HOPE-001 study on October 23, 2026, according to an issuer release. Takeda said arcotatug tavatecan met the study's dual primary endpoints of overall survival and progression-free survival in previously treated patients with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Market context: Market report Nikkei 225.
Takeda's release reported median overall survival of 10.2 months with arcotatug tavatecan versus 6.9 months with treatment of physician's choice. Median progression-free survival was 7.1 months versus 3.1 months, and the confirmed objective response rate was 37.4 percent versus 7.7 percent. The company said the findings support a planned regulatory filing in Japan. The compound remains investigational and has not been approved by the U.S. Food and Drug Administration or other regulatory authorities. These statements are supported by the Takeda release.
Weekend trading
At Lang & Schwarz, Takeda stock was at EUR 18.00 at 5:03 p.m. CET on October 25, 2026, during weekend trading. The next Xetra session is scheduled for October 26, 2026. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Takeda stock.
Clinical development
The G-HOPE-001 study enrolled 464 participants in Japan and China. Takeda said it plans to continue global development of arcotatug tavatecan and to initiate global Phase 3 trials in gastric and pancreatic cancer, subject to the development process described in its October 23 release.
